Slides on Emerging Insights on Adverse Events During ART and Implications for Treatment

Gain expert insight on the impact of emerging ART safety and tolerability data on ART initiation and switch strategies.
Joseph J. Eron, Jr., MD
Darcy Wooten, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 571 KB
Released: May 11, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

GEMS: ART resistance, adherence in persons with HIV on PrEP in Sub-Saharan Africa, reported by Clinical Care Options (CCO) from IAS 2021

Released: July 24, 2021

Interim results from the Phase II CALIBRATE study of lenacapavir in treatment-naive PLWH, reported by Clinical Care Options (CCO) from IAS 2021

Released: July 24, 2021

REACH study: adherence to dapivirine vaginal ring and oral PrEP among African females 16-21 years, in Clinical Care Options (CCO) report from IAS 2021

Released: July 24, 2021

Post-hoc analysis of TANGO assessed changes in quantitative and qualitative viral load through Week 96 and inflammatory biomarkers from baseline to Week 96, reported by Clinical Care Options (CCO) from IAS 2021

Released: July 22, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue